ArticleFrontiers in immunology2026
Case Report: Hemophagocytic lymphohistiocytosis in an infant associated with cytomegalovirus infection and X-linked primary immunodeficiency.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory disorder often driven by primary immunodeficiencies like X-linked lymphoproliferative syndrome (XLP) in infants. Case description: We report a 2-month-old male with primary immunodeficiency who developed HLH triggered by cytomegalovirus (CMV), confirmed via bone marrow PCR and hemophagocytosis findings. Initial immunophenotyping during acute hyperinflammation showed marked secondary disruptions across lymphocyte subpopulations, including severe lymphopenia in CD4+ T cells and pre-germinal center B cells. Genetic sequencing identified a pathogenic hemizygous variant in the Conclusion: This case demonstrates an atypical XLP-2 presentation where CMV, rather than Epstein-Barr virus, triggered HLH. Following stabilization and viral clearance, the patient successfully underwent allogeneic hematopoietic stem cell transplantation (HSCT) from a matched family donor. On day +30 post-HSCT, molecular chimerism confirmed 97.87% donor engraftment. On day +39 post-HSCT, the infant is clinically stable, actively recovering at last assessment from grade II cutaneous graft-versus-host disease (GvHD) under immunosuppression, with low-level CMV viral reactivation (951 copies/mL) managed under close surveillance. At the comprehensive 9-month follow-up from initial presentation, the patient maintained overall systemic stability without evidence of disease relapse or secondary organ dysfunction, highlighting the necessity of long-term monitoring in post-transplant cGvHD management, and proving the life-saving role of early genetic diagnosis and timely HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.